ATE226254T1 - Reagenz zur behandlung von arthritischen zustaenden - Google Patents

Reagenz zur behandlung von arthritischen zustaenden

Info

Publication number
ATE226254T1
ATE226254T1 AT95901907T AT95901907T ATE226254T1 AT E226254 T1 ATE226254 T1 AT E226254T1 AT 95901907 T AT95901907 T AT 95901907T AT 95901907 T AT95901907 T AT 95901907T AT E226254 T1 ATE226254 T1 AT E226254T1
Authority
AT
Austria
Prior art keywords
reagent
treatment
arthritic conditions
arthritic
conditions
Prior art date
Application number
AT95901907T
Other languages
English (en)
Inventor
Kenneth G Draper
Pamela Pavco
James Mcswiggen
John Gustofson
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Application granted granted Critical
Publication of ATE226254T1 publication Critical patent/ATE226254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95901907T 1993-11-12 1994-11-10 Reagenz zur behandlung von arthritischen zustaenden ATE226254T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15248793A 1993-11-12 1993-11-12
PCT/US1994/013129 WO1995013380A2 (en) 1993-11-12 1994-11-10 Method and reagent for treatment of arthritic conditions

Publications (1)

Publication Number Publication Date
ATE226254T1 true ATE226254T1 (de) 2002-11-15

Family

ID=22543137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901907T ATE226254T1 (de) 1993-11-12 1994-11-10 Reagenz zur behandlung von arthritischen zustaenden

Country Status (7)

Country Link
EP (1) EP0728205B1 (de)
JP (1) JPH09504949A (de)
AT (1) ATE226254T1 (de)
AU (1) AU704687B2 (de)
CA (1) CA2175824A1 (de)
DE (1) DE69431564D1 (de)
WO (1) WO1995013380A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4412096A (en) * 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
JP3844501B2 (ja) 1995-02-08 2006-11-15 タカラバイオ株式会社 癌の制御
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
EP1408111B1 (de) * 1995-10-26 2010-06-09 Sirna Therapeutics, Inc. Verfahren und Reagenz zur Behandlung von Krankheiten die von der Konzentration des Rezeptors für den Wachstumsfaktor der vaskulären Endothelzellen verursacht werden
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6280936B1 (en) 1997-06-09 2001-08-28 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6548657B1 (en) 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US20030195164A1 (en) * 2002-04-16 2003-10-16 Veli-Matti Kahari Novel ribozyme and its use
EP2350319A4 (de) * 2008-11-04 2012-09-12 South African Medical Res Council Oligonukleotide und verfahren zur bestimmung der anfälligkeit für weichgewebeläsionen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP1251170A3 (de) * 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Vergahren und Reagenz zur Behandlung von NF-kappaB abhängiger Tierischen Krankheiten

Also Published As

Publication number Publication date
WO1995013380A3 (en) 1995-06-22
AU1097395A (en) 1995-05-29
WO1995013380A2 (en) 1995-05-18
EP0728205A1 (de) 1996-08-28
EP0728205B1 (de) 2002-10-16
CA2175824A1 (en) 1995-05-18
AU704687B2 (en) 1999-04-29
JPH09504949A (ja) 1997-05-20
DE69431564D1 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
DE69431564D1 (de) Reagenz zur behandlung von arthritischen zustaenden
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
EP0654077A4 (de) Methode und reagenz zur behandlung einer tierischen krankheit.
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE59509510D1 (de) System zur Inkubation von Probeflüssigkeiten
DE69927960D1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ATE203545T1 (de) Substrate und inhibitoren von proteolytischen enzymen
DE69615193D1 (de) Vorrichtung für die aerobe biologische Behandlung von organische Substraten enthaltenden Abwässern
DE69913712D1 (de) Inhibitoren der bakteriellen nad synthetase
DE69837153D1 (de) Verhinderung des zellwachstums in einem gewässer
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
EP0489839A4 (en) Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
FR2783819B1 (fr) Procede microbiologique d'elimination d'un compose nitroaromatique present dans une solution ou dans un sol
DE69712453D1 (de) Vorrichtung zur Behandlung von organischen Abwasser mit Hilfe von Mikroorganismen
ATE356212T1 (de) O-fukosyltransferase
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
TR200000150T2 (tr) Amidlerin elde edilmesine mahsus usul.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
EP1118659A4 (de) Expressionssysteme zur funktionellen expression von nukleinsäuren
ATE307201T1 (de) Srcr domäne-enthaltendes protein
EP0666867A4 (de) Reagentien und methoden zur behandlung rheumatoischer arthritis.
MXPA03011715A (es) Moleculas de agrecanasa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties